People: Nanosphere Inc (NSPH.W)

Summary

Name	Age	Since	Current Position
Sheli Rosenberg	71	2013	Chairman of the Board
Michael McGarrity	49	2013	President, Chief Executive Officer, Director
J. Roger Moody	44		Chief Financial Officer, Vice President - Finance & Administration, Treasurer, Secretary
Kenneth Bahk		2013	Chief Strategy Officer
Chad Mirkin		2000	Director
Michael Ward		2013	Director
Andre de Bruin	65	2005	Independent Director
Lorin Randall	69	2008	Independent Director

» Insider Trading

Biographies

Name	Description
Sheli Rosenberg	Ms. Sheli Z. Rosenberg is the Chairman of the Board of Nanosphere, Inc. Ms. Rosenberg previously served as a director of the Company from 2002 to 2012. Ms. Rosenberg is currently Of Counsel at Skadden, Arps, Slate, Meagher & Flom LLP. Ms. Rosenberg is the retired chief executive officer, president and vice chairwoman of Equity Group Investments, Inc. She joined Equity Group Investments, Inc. in 1980 as General Counsel. She sits on the boards of three New York Stock Exchange corporations: Equity LifeStyle Properties, Inc., Strategic Hotels and Resorts, Inc. and Ventas, Inc.
Michael McGarrity	Mr. Michael K. McGarrity serves as President, Chief Executive Officer, Director of Nanosphere Inc. Mr.McGarrity joined Nanosphere in 2005 as Chief Marketing Officer. Mr. McGarrity, who has more than 18 years of sales and marketing experience in the medical device industry, joined Nanosphere after 13 years with Stryker Corporation. At Stryker, he served in leadership roles in marketing and strategic development, most recently as vice president of marketing for Stryker Instruments, where he also had executive general management responsibility for a newly created business focused on interventional pain management. Mr. McGarrity is a graduate of the University of Notre Dame and began his career in commercial banking in Chicago.
J. Roger Moody	Mr. J. Roger Moody, Jr., serves as Chief Financial Officer, Vice President - Finance & Administration, Treasurer, Secretary of Nanosphere Inc. Mr.Moody joined Nanosphere in 2007 as Chief Financial Officer and Vice President of Finance & Administration. He also serves as the Company’s Treasurer and Secretary. Mr.Moody has more than 20 years of experience in finance, corporate development and operations for high growth healthcare and technology companies. Previously, Mr. Moody spent six years at Medsn, a medical education company where he began as chief financial officer and was promoted to chief operating officer where he led Medsn’s United States and off-shore operations. Mr.Moody also served as chief financial officer and led corporate development for two private venture backed companies sold to strategic partners. Additionally, Mr. Moody provided mergers and acquisition and strategic advisory services to technology and healthcare companies for Volpe Brown Whelan & Company. Mr. Moody began his career at IBM. Mr.Moody received his B.S. from Syracuse University and his M.B.A. from the University of Chicago, Graduate School of Business.
Kenneth Bahk	Dr. Kenneth Bahk, Ph.D., has been appointed as Chief Strategy Officer of Nanosphere, Inc., effective April 23, 2013. Dr. Bahk has served as a Director of Investments at Lurie Investments, focusing on investments in diagnostics and life sciences. Dr. Bahk currently serves on the board of directors of Aperion Biologics, Geneweave Biosciences, and Viamet Pharmaceuticals. Dr. Bahk has been active in leadership positions for the premier diagnostic and molecular diagnostic organizations, and most recently was Chair of Strategic Opportunities, a committee charged with understanding key market trends and movements for the Association for Molecular Pathology. Prior to joining Lurie Investments in 2008, Dr. Bahk worked in Marketing and Market Development at Nanosphere, Inc. and led key efforts to identify assays and competitive positioning which shaped the current strategy for multiplexed molecular diagnostics. He received his PhD in biochemistry and molecular biology and MS in neurobiology and physiology from Northwestern University, and his MBA from the Kellogg School of Management.
Chad Mirkin	Dr. Chad A. Mirkin, Ph.D., is no longer Director of Nanosphere Inc., effective May 29, 2013. Dr. Mirkin is a scientist and pioneer in the development of ultra-high sensitivity and selectivity assays based upon nanostructures. He is currently the director of the Northwestern University International Institute for Nanotechnology and the George B. Rathmann Professor of Chemistry, Professor of Medicine, and Professor of Materials Science and Engineering. Dr.Mirkin received his undergraduate training at Dickinson College (B.S., 1986) and his graduate training at the Pennsylvania State University, where he completed his Ph.D. in chemistry in 1989. That same year, he moved to MIT as a National Science Foundation Postdoctoral Fellow. Dr. Mirkin joined the faculty at Northwestern University in 1991. He has won over 60 national and international awards for his research, including the ACS Nobel Signature Award, the NIH Director’s Pioneer Award, the Feynman Prize, the Leo Hendrik Baekeland Award, the ACS Award in Pure Chemistry, the Sackler Prize, the E. Bright Wilson Prize, and the Lemelson-MIT Prize. He is a member of the National Academy of Sciences, Institute of Medicine, and National Academy of Engineering.
Michael Ward	Mr. Michael J. Ward is appointed as the Director of Nanosphere, Inc. Mr. Ward joined Lurie Investments, Inc. in 2009 as a Vice President and is currently a Director, responsible for managing investment activities. Lurie Investments, Inc. beneficially owns 74,324 shares of the Company’s common stock and certain of its affiliates (such affiliates, together with Lurie Investments, Inc., being the “Lurie Entities”) beneficially own an aggregate of 14,650,413 shares of the Company’s common stock. Prior to joining Lurie Investments, Inc., Mr. Ward gained over 15 years of investment banking experience at Credit Suisse, Prudential Securities, Dresdner Kleinwort Wasserstein, BMO and Leerink Swann. Mr. Ward is a member of the board of directors of CytoPherx, Inc., an acute renal failure-focused therapeutic medical device company based in Ann Arbor, MI, and Discera, Inc., a MEMS (micro-electrical mechanical system) products company based in San Jose, CA.
Andre de Bruin	Mr. André De Bruin serves as an Independent Director of Nanosphere Inc., since June 2005. Mr. de Bruin has more than 35 years of global healthcare industry experience spanning the bio-pharmaceutical, medical device and diagnostics markets. Most recently, Mr. de Bruin was the founder and chief executive officer of DuraPorts Inc., a manufacturer of steel and fabric structures. He also serves on the board of Directors of NxThera Inc., a medical device company based in St. Paul, MN, where he is Chairman of the Board. Prior to his retirement in 2004 as executive chairman of Quidel Corporation’s board of directors, Mr. de Bruin served as the company’s chief executive officer from 1998 until 2001. He was president and chief executive officer of Somatogen and was elected chairman in 1996. Prior to joining Somatogen, Mr. de Bruin was chairman, president and chief executive officer of Boehringer Mannheim Corporation, a global healthcare concern subsequently acquired by Hoffman-La Roche. Past experience includes advisory services for Ferrer, Freeman and Company, LLC and various boards of directors. Mr. de Bruin graduated from the University of Potchefstroom in South Africa, where he earned a B.S. in finance, economics and business.
Lorin Randall	Mr. Lorin Jeffry Randall serves as an Independent Director of Nanosphere Inc. He has served as a member of Company's board of directors and the chairman of the audit committee since 2008. Mr. Randall is a financial consultant and also serves on the boards of the following healthcare companies: Tengion, Inc., Athersys, Inc. and Acorda Therapeutics, Inc. Mr. Randall previously served as senior vice president-chief financial officer of Eximias Pharmaceutical Corporation, a development stage provider of oncology therapeutics. Mr. Randall held the same position at i-STAT Corporation, a manufacturer of medical diagnostic devices, which was acquired by Abbott Laboratories in 2004. His career also includes senior management positions at CFM Technologies, a semiconductor manufacturing equipment company; Greenwich Pharmaceutical Corporation, a development stage provider of immune system disease therapeutics; and Surgilase, a provider of surgical lasers to hospitals and clinics. Mr. Randall received a B.S. in accounting from The Pennsylvania State University and an M.B.A. from Northeastern University.

Basic Compensation

Name	Fiscal Year Total
Sheli Rosenberg	--
Michael McGarrity	298,453
J. Roger Moody	303,966
Kenneth Bahk	--
Chad Mirkin	--
Michael Ward	--
Andre de Bruin	--
Lorin Randall	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Sheli Rosenberg	0	0
Michael McGarrity	0	0
J. Roger Moody	0	0
Kenneth Bahk	0	0
Chad Mirkin	0	0
Michael Ward	0	0
Andre de Bruin	0	0
Lorin Randall	0	0

Insider Trading

Name	Shares Traded	Price
MIRKIN CHAD A	10,000	$1.96
ROSENBERG SHELI Z	50,000	$1.97
SLEZAK MARK	2,902,407	$0.00
SLEZAK MARK	5,006,136	$0.00
SLEZAK MARK	2,274,096	$0.00
SLEZAK MARK	1,000,000	$2.40
SLEZAK MARK	229,746	$2.05
SLEZAK MARK	79,329	$1.98
SLEZAK MARK	40,000	$1.95
SLEZAK MARK	10,000	$1.98
SLEZAK MARK	5,000	$1.95
SLEZAK MARK	20,000	$1.96
SLEZAK MARK	13,116	$1.90
SLEZAK MARK	15,000	$1.85
SLEZAK MARK	317,500	$1.75
SLEZAK MARK	25,000	$1.75
SLEZAK MARK	88,900	$1.71
SLEZAK MARK	30,000	$1.69
SLEZAK MARK	10,000	$1.69
SLEZAK MARK	5,505	$1.70
SLEZAK MARK	35,000	$1.71
PATNO TIMOTHY J	40,275	$2.00
GIBBONS WINTON G	2,000	$1.58
GIBBONS WINTON G	13,230	$1.60
GIBBONS WINTON G	5,092	$1.61

» Full list on Insider Trading

People: Nanosphere Inc (NSPH.W)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: